Pieter Annaert
Overview
Explore the profile of Pieter Annaert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
187
Citations
2156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heylen S, Nicolai J, Van Asten S, Tuytelaars A, De Wagter K, Snoeys J, et al.
Drug Metab Dispos
. 2025 Mar;
53(3):100045.
PMID: 40086408
To reduce the drug attrition due to failure in clinical trials, an early accurate hepatic clearance (CL) prediction for small molecule drugs is critical. However, the routinely used in vitro...
2.
De Vos K, Mols R, Armoudjian Y, Augustijns P, Annaert P
Arch Toxicol
. 2025 Mar;
PMID: 40029369
Modelling and simulation of hepatic bile acids (BA) kinetics is instrumental to understand mechanisms underlying drug-induced cholestasis (DiCho). A recent study has shown that the loss of tankyrase1/2 (TNKS1/2) matured...
3.
De Vos K, Mols R, Chatterjee S, Huang M, Augustijns P, Wolters J, et al.
AAPS J
. 2025 Feb;
27(2):51.
PMID: 40016501
Understanding the kinetics of hepatic processes, such as bile acid (BA) handling and cellular aerobic metabolism, is crucial for advancing our knowledge of liver toxicity, particularly drug-induced cholestasis (DiCho). This...
4.
5.
Ozbey A, Meneses-Lorente G, Simmons B, McCallum S, Annaert P, Parrott N, et al.
Clin Pharmacokinet
. 2025 Feb;
PMID: 39934586
Background And Objectives: This study investigates the pharmacokinetics (PK) of entrectinib and its metabolite M5 (CYP3A4 substrates) in patients with hepatic impairment (HI) and applies physiologically based pharmacokinetic (PBPK) modelling...
6.
Vander Elst Z, Stultjens T, Annaert P, Clarke P, Iglesias-Platas I, Agathos E, et al.
J Clin Pharmacol
. 2025 Feb;
PMID: 39930975
Hypoxic-ischemic encephalopathy (HIE) resulting from perinatal asphyxia presents a substantial risk of mortality and long-term sequelae in neonates. Therapeutic hypothermia (TH) improves both short- and long-term outcomes in near-term/term neonates...
7.
Gijsen M, Vanneste D, Annaert P, Debaveye Y, Wauters J, Spriet I
Ther Drug Monit
. 2024 Dec;
PMID: 39661123
Background: Ceftriaxone is a first-line beta-lactam antibiotic used in diverse clinical settings. Owing to pharmacokinetic alterations, ceftriaxone therapeutic drug monitoring is currently recommended for patients in the intensive care unit....
8.
La Mantia D, Nauwelaerts N, Bernardini C, Zannoni A, Salaroli R, Lin Q, et al.
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519007
It is currently impossible to perform an evidence-based risk assessment for medication use during breastfeeding. The ConcePTION project aims to provide information about the use of medicines during lactation. The...
9.
Melander E, Nielsen E, Lindqvist A, Hovd M, Gandia P, Panchaud A, et al.
Basic Clin Pharmacol Toxicol
. 2024 Nov;
136(1):e14100.
PMID: 39497323
Cetirizine is an antihistamine commonly used to treat allergic rhinitis and other allergic conditions. Cetirizine is often prescribed to breastfeeding mothers although there is limited information on infant exposure via...
10.
Stroe M, De Clerck L, Dhaenens M, Dennis R, Deforce D, Carpentier S, et al.
Basic Clin Pharmacol Toxicol
. 2024 Sep;
135(5):620-640.
PMID: 39315536
Asphyxiated neonates often undergo therapeutic hypothermia (TH) to reduce morbidity and mortality. As perinatal asphyxia and TH impact neonatal physiology, this could also influence enzyme functionality. Therefore, this study aimed...